UNSPSC 51382201: Clofurac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H15ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0V7WAB3NV4, chemically known as 5-chloro-6-cyclohexyl-2,3-dihydrobenzofuran-2-one but generally known as clofurac, which bears US NIH Compound Identifier 68806. European Medicines Agency schedules Clofurac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06713MIG.

UNSPSC 51382201 Clofurac is a Commodity code that, based on recent state and local solicitations, encompasses pharmaceutical products including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter medications procured for public health and community health initiatives. State and local buyers under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The solicitations show governments buying drugs and related health products either directly for county distribution or through cooperative frameworks that aggregate purchasing across multiple jurisdictions and authorized wholesalers. Vendors must typically hold current Good Manufacturing Practices certification, comply with the Drug Supply Chain Security Act, maintain relationships with authorized pharmaceutical wholesalers, and demonstrate pricing flexibility through various net-price models. Insurance requirements often include commercial general liability ($5 million per occurrence in the cooperative context), workers' compensation, and professional liability coverage.

Recent activity spans Florida, Texas, and the multistate cooperative framework covering Minnesota and Oregon. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, including shipping costs in vendor proposals; the contract carried a two-year initial term with a one-year renewal option and was potentially funded through FEMA. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting with pharmaceutical manufacturers outside existing pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities through AmerisourceBergen, Cardinal Health, and Morris & Dickson; award decisions weight price competitiveness at 75 percent, with contract effectiveness set for July 1, 2026, and performance penalties ranging from $200 to $1,500 per violation.